medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2000, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2000; 47 (4)

The clinical laboratory and the coronary risk evaluation

Terrés-Speziale AM

Language: Spanish
References: 70
Page: 202-218
PDF size: 105.04 Kb.


ABSTRACT

Mexico is involved on a demographic and epidemiological transition with significative growth of chronic and degenerative diseases. Atherosclerosis and cardiovascular diseases are prevalent with important elevations on morbidity and mortality statistics. Among the aetiology of coronary diseases non modifiable factors have been established including genetics, sex, race and age plus modifiable factors such as physical activity, smoking, obesity, diabetes, hypertension and blood lipids. There is a considerable amount of new information about lipids, lipoproteins, cellular receptors, contraceptive effects on coagulation and fibrinolysis and thrombosis plus new knowledge of pollution’s impact on free radicals and homocysteine on lipoprotein oxidation which make them prone to form the atheromatose plaque. The main purpose of this article is to review the biochemistry and pathophysiology of atherogenesis thrombogenesis and fibrinolysis plus the indication and interpretation of laboratory tests in order to establish appropriate diagnosis & preventive strategy.


REFERENCES

  1. Terrés Speziale AM, et al. Utilidad del laboratorio en el individuo supuestamente Sano. Rev Mex Patol Clin 1987; 32: 2.

  2. Statland BE. Clinical Decision Levels For Laboratory Tests. NJ, USA. Medical Economic Books; 1983.

  3. Barnett RN. Clinical Laboratory Statistics. Boston, USA. Little Brown & Co.; 1971.

  4. IFCC Expert panel on theory of reference values. Part 1. The concept of reference values. Clin Chem 1979; 25: 1506.

  5. IFCC Expert panel on theory of reference values. Part 5. Statistical treatment of colle C ted reference values. Determination of reference limits. J Clin Chem Clin Biochem 1982; 20: 841.

  6. IFCC Expert panel on theory of reference values. Part 6. Presentation of observed values related to reference values. J Clin Chem Clin Biochem 1983; 21: 749.

  7. Cueto L, Barrios R, Pérez GC, et al. Prevención de la aterosclerosis coronaria (I) Conceptos patológicos y etiopatológicos básicos. Arch Inst Cardiol Mex 1987:57:531.

  8. Soberón G, Kumate J, Laguna J. La salud en México. Testimonios. Biblioteca de La Salud. México, DF; 1988.

  9. Cueto L, Barrios R, Pérez GC, et al. Prevención de la aterosclerosis coronaria (Il) topografía y morfología de las lesiones protruyentes. Implicaciones epidemiológicas, diagnósticas y terapéuticas. Arch Inst Cardiol Mex 1987; 57: 439.

  10. Cueto-García L. Editorial actualizando la magnitud del problema de la aterosclerosis en México. Arch Inst Cardiol Mex 1989; 59: 7.

  11. Cueto García L, Brito E, Barrera Guerrero J, Gutiérrez Ávila MC. Prevención de la aterosclerosis coronaria (III) prevalencia de factores de riesgo en burócratas de la ciudad de México DF. Arch Inst Cardiol Mex 1989; 59: 19.

  12. Viniera Osario A, Cueto García L, Brito E, Barrera Guerrero J Gutiérrez Ávila MC. Prevención de la aterosclerosis coronaria (IV) prevalencia de aterosclerosis aórtica en México DF. Arch Inst Cardiol Mex 1989; 59: 415.

  13. Luna Castellanos G, Cueto García L, Barrios Del Valle R, Viniera Osario A. Prevención de la aterosclerosis coronaria (V) prevalencia de rigidez ateromatosa no estenótica en hombres muertos accidentalmente en México DF. Arch Inst Cardiol Mex 1989; 59: 449.

  14. Domínguez Márquez O, Camacho Solís R, Villarroel Vargas R, Tudón Garcés H, Campos Fernández MC, Moras Sandoval RM. La mortalidad de los trabajadores del IMSS de 1983 a 1987. Salud Pub Mex 1992; 34: 58-68.

  15. Secretaría de Salud. Encuesta nacional de enfermedades crónicas. México. Dirección General de Epidemiología S.S.; 1993.

  16. Camacho Hernández RC, Corona Muñiz I, Vázquez Martínez JI, Martínez Rodríguez F, Escobedo de La Peña J. Factores de riesgo para cardiopatía isquémica en México: un estudio de casos clínicos y testigos. Arch Inst Cardiol Mex 1996; 65: 315-332.

  17. González Villalpando C, Martínez Díaz S, Arredondo Pérez B, González Villalpando ME, Rivera Martínez D, Stern M. Factores de riesgo cardiovascular en la ciudad de México. Estudio en población abierta. Rev Med IMSS 1996; 34: 461-466.

  18. Fredrickson DS, Lees RS. A System for Phenotyping Hiperlipoproteinemia. Circulation 1965; 31: 321.

  19. Levy RI, Fredrickson DS. Diagnosis and management of hiperlipoproteinemia. Am J of Cardiology 1968; 22: 576.

  20. Havel RJ. Approach to the patient with hiperlipidemia. In: The Medical Clinics of North American 1972; 66(2): 319.

  21. Friedewald W, Levy RI, Frederickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499.

  22. Miller GJ, et al. HDL-C and the development of ischaemic heart disease. Lancet 1975; 1: 16.

  23. Castelli WP. HDL-C and other lipids in CHD. Circulation 1977; 55: 767.

  24. Tavia G, et al. High density lipoprotein as a protective factor against CHD. The Am J of Medicine 1977; 62: 707.

  25. Castelli WP. HDL-C and other lipids in CHD. Circulation 1977; 55: 767.

  26. Grundy SM. Hypertriglyceridemia: mechanisms, clinic significance and treatment. In The Medical Clinics of North America 1982; 66(2): 519.

  27. Mahley RW. Atherogenic hyperlipoproteinemia. In: The Medical Clinics Of North America 1982; 66(2): 375.

  28. Bierman EL, Glomset J. A disorders of lipid metabolism. In: Williams Textbook of Endocrinology 7a. Ed: W.B. Saunders Company; 1985:1118-1136.

  29. Levy RI. Decling mortality in CHD. Arteriosclerosis 1985; I: 312.

  30. Arky RA, Permian AJ. Hyperlipoproteinemia. In: Medicine 1, Scientific American; 1986:9(11).

  31. NIH: Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36.

  32. Bachorik PS, Levy RI, Rifkind BM. Lipids and dyslipoproteinemia. In: J Bernard Henry. Clinical Diagnosis & Management by Laboratory Methods. 18th Edition WB Saunders Company Philadelphia; 1991.

  33. Terrés-Speziale AM, González-Marmolejo R, González-Cruz M, Sánchez Girón F. Evaluación de los lípidos sanguíneos como índice de riesgo coronario. Rev Mex Patol Clin 1986; 33: 135.

  34. Terrés-Speziale AM, Sáenz De Miera A. Hiperlipoproteinemias. Clínicas Médicas Mexicanas AMIM. 1987; 1: 1.

  35. Garber AM, Harold CS, Littenberg B. Screening asymptomatic adults for cardiac risk factors the serum cholesterol level. Ann Int Med 1989; 11: 622.

  36. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. Nejm 1991; 325: 373.

  37. Terrés Speziale AM, González Cruz M, González Solís R Evaluación de aterogénesis en 5 grupos de pacientes. Rev Mex Patol Clin 1991; 38: 126.

  38. Terrés Speziale AM, et al. Evaluación del riesgo aterogénico por medio de los lípidos sanguíneos. Anales Médicos HABC 1991; 36: 118-125.

  39. Terrés Speziale AM, Gutiérrez Reyes M. Evaluación del riesgo aterogénico, comparación de dos metodología. Rev Mex Patol Clin 1993; 40: 58-61.

  40. Terrés Speziale AM, Gutiérrez Reyes GM. Evaluación de riesgo aterogénico con carga oral de glucosa . Rev Mex Patol Clin 1994; 41: 128-134.

  41. Terrés Speziale AM, Canahuati Rock L. Aterogénesis y glicosilación de las proteínas en diabetes mellitus. Rev Mex Patol Clin 1996; 43: 67-79.

  42. Terrés Speziale AM; Bello Madrigal NM. Lípidos: aplicación de niveles de decisión clínica y evaluación de su cronobiología en México. Rev Med IMSS 2001, En Prensa.

  43. Von Kaulla E, Droegemuller W, et al. At-III depression and thrombin generation acceleration in women taking oral contraceptives. Surg Gynecol Obstet 1971; 133: 609.

  44. Sagar S, Thomas DP, Stamakis JD. Oral contraceptive at-III activity and deep vein thrombosis. Lancet 1976; 1: 509.

  45. Gruchow HW, Anderson AJ, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954.

  46. High KA. Antithrombin III, protein C and protein S: natural occurring anticoagulant proteins. Arch Pathol Lab Med 1988; 112: 28.

  47. Terrés Speziale AM, Rubio Lotvin B, Kuttohara A, Rodríguez MC, Kauffer HM. Desogestrel/etinil estradiol: efectos sobre el metabolismo de los lípidos y riesgos coronarios: estudio comparativo. Investigación Médica Internacional. 1988; 14: 225.

  48. Terrés Speziale AM, Rubio Lotvin B. Efectos comparativos de tres anticonceptivos orales en los lípidos sanguíneos. Estudio prospectivo durante 5 años. Rev Latinoamericana de Esterilidad y Fertilidad 1991; 5: 23.

  49. Schaeffer EJ. Lp- (a) levels and risk of CHD in men. JAMA 1994; 271: 999-1003.

  50. Terres W. Rapid progression of coronary artery disease in patients with elevated Lp-a. Circulation 1995; 91: 948-50.

  51. Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia: an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996; 105: 709-722.

  52. Jialal I, Devaraj S. Low density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Clin Chem 1996; 42: 498-506.

  53. Cordoba-Porras A, Sanchez-Quesada JL, Gonzalez-Sastre F, Ordonez-Llanos J, Blanco-Vaca F. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med 1996; 74: 771-776.

  54. Raitakari OT, Pitkanen OP, Lehtimaki T, Lahdenpera S, et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30: 97-102.

  55. Dahlen GH. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997; 52: 272-280.

  56. Chiesa R, Melissano G, Castellano R, Astore D, et al. In search of biological markers of high-risk carotid artery atherosclerotic plaque: enhanced ldl oxidation. Ann Vasc Surg 1998; 12: 1-9.

  57. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening and treatment. Arch Int Med 1998; 158: 1301-1306.

  58. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med 1998; 48: 31-62.

  59. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-1843.

  60. Kane JP, Malloy MJ. Treatment of hypercholesterolemia. In: The Medical Clinics of North America 1982; 66(2): 537.

  61. Connor WE. Connor SL. The dietary treatment of hyperlipemia. In: The Medical Clinics of North American 1982; 66(2): 485.

  62. NIH: Consensus Conference: Treatment of Hypertriglyceridemia. Jama 1984; 251: 1196.

  63. The Lipid Research Clinics. Coronary primary prevention trial results I: reduction in the incidence of CHD. Jama 1984; 251: 351.

  64. The Lipid Rescarch Clinics, Coronary Primary Prevention Trial Results II: The relationship of reduction in incidence of CHD to cholesterol lowering. Jama 1984; 251: 365.

  65. Harlan WR. An educational view of a national initiative to lower plasma lipid leveis. Jama 1985; 253: 2087.

  66. Consensus Conference: Lowering blood cholesterol to prevent heart disease. Jama 1985; 253: 2080.

  67. Kashyap ML. Basic considerations in the reversal of atherosclerosis. Am J Cardiol 1989; 63: 56.

  68. Assmann G. At what levels of total, low or high density lipoprotein cholesterol should diet/drug therapy be initiated. European Guidelines. Am J Cardiol 1990; 1878-1882.

  69. SMNE: Diagnóstico y tratamiento de las hiperlipidemias en México. Recomendaciones de la Sociedad Mexicana de Nutrición y Endocrinología. Ac. Rev Mex Cardiol 1991; 213: 97-105.

  70. Luengas Escudero M, Mejía Arranguré JM, Cruz Ruiz M, Aguirre Gas H, Carreño Mejía E, Lerdo De Tejada A. La dislipidemia asociada con los alimentos. Gac Med Méx 1997; 133: 295-299.




2020     |     www.medigraphic.com